Needham Starts Aastrom Biosciences (ASTM) at Buy; Late-Stage Cell Therapy Product Likely First to Market
Tweet
Share
E-mail
Get Alerts ASTM Hot Sheet
Price: $2.77 --0%
Rating Summary:
8 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
8 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Needham & Company initiates coverage on Aastrom Biosciences (NASDAQ: ASTM) at 'Buy', price target of $5.00.
Analyst, Chad Messer, said, "Aastrom is currently enrolling the pivotal REVIVE-CLI Phase III trial for its autologous cell therapy product ixmyelocel-T in no-option critical limb ischemia (CLI) patients under a Special Protocol Assessment (SPA) with the FDA. We expect results in 2H:14. We believe ixmyelocel-T is one of only a handful of clinically well validated cell therapies for cardiovascular disease and that Aastrom has first mover advantage in CLI. Aastrom is also developing ixmyelocel-T in dilated cardiomyopathy (DCM), and we look for interim data from a Phase IIb RENEW-DCM trial in 2H:13."
For an analyst ratings summary and ratings history on Aastrom Biosciences click here. For more ratings news on Aastrom Biosciences click here.
Shares of Aastrom Biosciences closed at $2.16 yesterday.
Analyst, Chad Messer, said, "Aastrom is currently enrolling the pivotal REVIVE-CLI Phase III trial for its autologous cell therapy product ixmyelocel-T in no-option critical limb ischemia (CLI) patients under a Special Protocol Assessment (SPA) with the FDA. We expect results in 2H:14. We believe ixmyelocel-T is one of only a handful of clinically well validated cell therapies for cardiovascular disease and that Aastrom has first mover advantage in CLI. Aastrom is also developing ixmyelocel-T in dilated cardiomyopathy (DCM), and we look for interim data from a Phase IIb RENEW-DCM trial in 2H:13."
For an analyst ratings summary and ratings history on Aastrom Biosciences click here. For more ratings news on Aastrom Biosciences click here.
Shares of Aastrom Biosciences closed at $2.16 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OncoCyte Corp (OCX) PT Raised to $4.25 at Needham
- Needham Starts Viavi Solutions (VIAV) at Hold
- JPMorgan Starts Lovisa Holdings Ltd (LOV:AU) at Neutral
Create E-mail Alert Related Categories
New CoverageRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
